Critical Care Reviews
Current standard of care across critical illness, organized by treatment area — with the landmark trials and society guidelines behind each recommendation.
Each review summarizes how critically ill patients are managed today, area by area. Every dose, threshold, and figure is taken from the cited primary source (DOI + PMID) and reviewed by the DosePilot Medical Team. Pick a topic from the menu; the current evidence our reviews are built on is listed below.
Evidence & guideline basis
2026
2025
2025
2025
SRLF–GFRUP — RRT in the ICUAKI & CRRT
45 statements on RRT timing, modality, dose, anticoagulation & weaning. PubMed →
2025
BigpAK-2 (Lancet)AKI & CRRT
Biomarker-guided KDIGO care bundle cut moderate–severe post-op AKI. PubMed →
2024
2024
2024
2023
2023
AABB 2023 Red-Cell Transfusion GuidelineTransfusion
Restrictive Hb 7 g/dL for most adults (8 ortho/CVD; 7.5 cardiac surgery). PubMed →
2023
MINT — Transfusion in Myocardial InfarctionTransfusion
Acute MI + anemia: liberal trend on primary; restrictive had higher cardiac death. PubMed →
2023
2023
2021
AKIKI-2 (Lancet)AKI & CRRT
Over-delaying RRT in severe AKI gave no extra benefit and signaled harm. PubMed →
2020
STARRT-AKI (NEJM)AKI & CRRT
Accelerated RRT gave no survival benefit and more dialysis dependence. PubMed →
2019
2015
PROPPR (JAMA)Transfusion
Massive hemorrhage: 1:1:1 vs 1:1:2 equal mortality, faster hemostasis. PubMed →
2011
2010
CRASH-2 (Lancet)Transfusion
Tranexamic acid cuts bleeding death in trauma when given within 3 h. PubMed →
Disclaimer. Educational summaries for clinicians — not a substitute for individual clinical judgment or institutional protocols. Recommendation strengths are quoted from the cited guidelines; reviewed by the DosePilot Medical Team (Jun 2026).